CONNECTING PATIENTS TO ACTEMRA

ACTEMRA SC Payer Coverage Status

The IL-6 inhibitor preferred on commercial formularies, covering >100 million lives nationwide.

Genentech patient support services help patients access and learn about ACTEMRA at any point during their treatment

If your patients:

Need help understanding insurance coverage and related financial responsibilities, Genentech Access Solutions is here to help.

  • Contact your Genentech representative if you have questions about coverage or financial assistance options

Do not have insurance coverage or have financial concerns and meet certain eligibility criteria, the Genentech Patient Foundation may be able to provide free medicine.*

Have insurance and need help paying for their medicine, Affordability Options may be available.

The final amount owed by patients may be as little as $5, but may vary depending on the patient’s health insurance plan.

Want information and resources about ACTEMRA, ACTEMRA & You™ provides answers to their questions.

*To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have pursued all other forms of financial assistance and meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet income requirements.

This ACTEMRA Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.

Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.

All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit https://racopay.com/actemra/terms-and-conditions for the full list of Terms and Conditions.

§Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient’s disease state.

RA=rheumatoid arthritis; SC=subcutaneous.